U.S. Markets closed

Oramed Pharmaceuticals Inc. (ORMP)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
8.56-0.02 (-0.23%)
At close: 4:00PM EDT
People also watch

Oramed Pharmaceuticals Inc.

Hi-Tech Park 2/4
Jerusalem 91390
972 2 566 0001

Full Time Employees

Key Executives

Mr. Nadav Kidron Esq.Chief Exec. Officer, Pres and Exec. Director486.18kN/A43
Mrs. Yifat Zommer CPAChief Financial Officer, Treasurer and Sec.177.25kN/A43
Mr. Joshua HexterChief Operating Officer and VP of Bus. Devel.N/AN/A47
Dr. Miriam Kidron Ph.D.Chief Medical & Technology Officer, Chief Scientific Officer and Director353.15kN/A77
Dr. Roy Eldor M.D., Ph.D.Chief Medical Advisor and Member of the Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.

Corporate Governance

Oramed Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.